Filed Pursuant to Rule 424(b)(3)
Registration No. 333-274564
Prospectus Supplement No. 31
(To Prospectus dated December 15, 2023)
ALLURION TECHNOLOGIES, INC.
Up to 56,548,268 Shares of Common Stock
This prospectus supplement no. 31 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Registration Statement on Form S-1/A (Registration Statement No. 333-274564). This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on December 19, 2025 (the “8-K”). Accordingly, we have attached the 8-K to this Prospectus Supplement.
This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.
Our common stock is listed on The New York Stock Exchange (“NYSE”) under the symbol “ALUR” and our public warrants are listed on the NYSE under the symbol “ALUR.WS”. On December 19, 2025, the last quoted sale price for shares of our common stock as reported on the NYSE was $1.47 per share, and the last quoted sale price for our public warrants as reported on the NYSE was $0.02 per warrant.
We are an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 26 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is December 22, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 2025
Allurion Technologies, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-41767 | 92-2182207 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| 11 Huron Drive Natick, Massachusetts |
01760 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s Telephone Number, Including Area Code: (508) 647-4000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common stock, par value $0.0001 per share | ALUR | The New York Stock Exchange | ||
| Warrants to purchase 0.056818 shares of common stock, each at an exercise price of $202.50 per share of common stock | ALUR WS | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On December 18, 2025, Allurion Technologies, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on the seven proposals set forth below, each of which is described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 24, 2025 (the “Proxy Statement”).
The following actions were taken at such meeting:
| 1. | The following nominees were re-elected to serve on the Company’s Board of Directors (the “Board”) until the Company’s 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified, based on the following votes: |
| Nominee |
Votes For | Withheld | Broker Non-Votes | |||||||||
| Omar Ishrak, M.D. |
3,633,612 | 109,159 | 1,508,891 | |||||||||
| Douglas Hudson |
3,582,668 | 160,103 | 1,508,891 | |||||||||
| R. Jason Richey |
3,563,130 | 179,641 | 1,508,891 | |||||||||
| 2. | The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of such vote were as follows: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 5,191,443 | 22,708 | 37,511 | 0 | |||||||||||
| 3. | The stockholders approved an amendment and restatement of the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan (the “2023 Plan” and as amended and restated, the “Amended and Restated Plan”) to (i) increase the number of shares of common stock, par value $0.0001 per share (the “common stock”), of the Company authorized for issuance thereunder (with a corresponding increase to the number of shares of common stock that may be issued in respect of incentive stock options), (ii) amend the definition of Fully-Diluted Shares Outstanding, (iii) lower the non-employee director compensation limit, and (iv) extend the term of the plan. The results of such vote were as follows: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 3,374,602 | 240,580 | 127,589 | 1,508,891 | |||||||||||
| 4. | The stockholders approved the repricing of certain outstanding stock options that were granted under the 2023 Plan. The results of such vote were as follows: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 3,421,017 | 320,127 | 1,627 | 1,508,891 | |||||||||||
| 5. | The stockholders approved the issuance of shares of common stock upon conversion of the Company’s Series B Preferred Stock to comply with New York Stock Exchange (“NYSE”) Listing Rule 312.03(b)(i), 312.03(c) and 312.03(d). The results of such vote were as follows: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 3,462,336 | 224,015 | 56,420 | 1,508,891 | |||||||||||
| 6. | The stockholders approved the issuance of shares of common stock upon the exercise of certain private placement warrants for purposes of complying with NYSE Listing Rule 312.03(c). The results of such vote were as follows: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 3,519,769 | 214,141 | 8,861 | 1,508,891 | |||||||||||
| 7. | The stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to combine the outstanding shares of the Company’s common stock into a lesser number of outstanding shares, by a ratio of not less than 1-for-1.5 and not more than 1-for-20, with the exact ratio to be set within this range by the Board in its sole discretion. The results of such vote were as follows: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 4,738,011 | 499,230 | 14,421 | 0 | |||||||||||
The proposal to adjourn the Annual Meeting, if necessary, to permit further solicitation and vote of proxies in the event that there were insufficient votes in favor of Proposals 3, 4, 5, 6 and 7 was not voted upon at the Annual Meeting since there were sufficient votes to approve Proposals 3, 4, 5, 6 and 7.
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALLURION TECHNOLOGIES, INC. | ||||||
| Date: December 19, 2025 | By: | /s/ Brendan Gibbons | ||||
| Name: | Brendan Gibbons | |||||
| Title: | Chief Legal and People Officer | |||||